Understand the source comparison
Peptides for Heart Disease Prevention: Clinical Trial Comparison
Thymosin Alpha-1 T-regulatory cell upregulation, cytokine suppression 31% CRP reduction, 40% slower cIMT progression (12-week RCT, Atherosclerosis 2022) 1.6mg SC twice weekly, minimum 12 weeks hs-CRP, IL-6, TNF-alpha, carotid IMT Strongest evidence for inflamm
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymosin Alpha-1
- T-regulatory cell upregulation, cytokine suppression
- 31% CRP reduction, 40% slower cIMT progression (12-week RCT, Atherosclerosis 2022)
- 1.6mg SC twice weekly, minimum 12 weeks
- hs-CRP, IL-6, TNF-alpha, carotid IMT
- Strongest evidence for inflammatory cardiovascular risk. Ideal for metabolic syndrome with elevated CRP (>3.0 mg/L)
- Hexarelin
- eNOS activation, arterial compliance improvement
- 1.2 m/s reduction in pulse wave velocity, 15% vascular compliance gain (Phase 2, University of Turin)
- 100mcg SC daily (evening), 8–12 weeks
- Pulse wave velocity, flow-mediated dilation, blood pressure
- Direct endothelial benefit. Best for early-stage hypertension or arterial stiffness without overt atherosclerosis
- MK-677 (Ibutamoren)
- IGF-1 upregulation, ghrelin mimetic
- 60–90% IGF-1 increase, endothelial function improvement in aging cohorts (Japanese observational study)
- 12.5–25mg oral daily, 8–16 weeks
- IGF-1, fasting glucose, lipid panel
- Orally active alternative to injectable GH secretagogues. Monitor glucose closely (can impair insulin sensitivity at higher doses)
- SS-31 (Elamipretide)
- Cardiolipin stabilisation, mitochondrial ROS reduction
- 18% NT-proBNP reduction, improved diastolic function in HFpEF patients (2021 Phase 2 trial)
- 0.25mg/kg IV infusion, 4 weeks
- NT-proBNP, echocardiographic diastolic parameters, oxidative stress markers
- Most advanced mitochondrial-targeted peptide in cardiovascular trials. Currently investigational, not available as research peptide
- Cartalax
- Mitochondrial signalling (hypothesised cardiolipin interaction)
- Preclinical oxidative stress reduction. No large-scale human cardiovascular RCTs as of 2026
- Variable (research protocols use 5–10mg SC weekly)
- Oxidative stress markers (8-OHdG, MDA), mitochondrial function assays
- Mechanistic rationale is strong, but clinical cardiovascular evidence is sparse compared to thymosin or GH secretagogues